跳至主要内容
临床试验/NCT00128986
NCT00128986已完成1 期

A Phase I Study of Tomotherapy in Patients With Benign Brain Tumour

AHS Cancer Control Alberta2 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2005年5月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
49
试验地点
2
主要终点
safety and adverse effects

研究概览

简要总结

Although malignant brain tumors are the most common type of primary brain tumor, there are a number of other benign brain tumors that exist. Many difficulties exist with treating these tumors that have led to controversies in the best treatment. A common issue among these brain tumors is the risk of long term side effects from treatment. What limits the use of curative radiation therapy is the ability to deliver a maximal dose to the tumor while minimizing the amount of radiation to the normal structures in the brain. A new method of delivering radiation, called tomotherapy, has been acquired at the Cross Cancer Institute (CCI) and will be used in this study. It has the ability to deliver a high dose of radiation to the tumor while minimizing the amount of radiation to normal brain structures. This study will use this method of radiation therapy to deliver radiation and see if the long term side effects from radiation therapy can be reduced.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histopathologically confirmed newly diagnosed base of skull benign tumour
  • Karnofsky Performance Status (KPS) equal to or greater than 70

排除标准

  • Brain metastases or recurrent tumour
  • Prior radiotherapy (RT) to head or neck
  • No prior chemotherapy or radiosensitizer

结局指标

主要结局

safety and adverse effects

时间窗: Trial Completion

次要结局

  • efficacy and survival(Trial completion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验